These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2832966)

  • 1. Antithrombin III in patients with hepatocellular carcinoma.
    Leone G; De Stefano V; Garufi C; Ferrelli R; Cassano A; Grieco A
    Thromb Haemost; 1987 Dec; 58(4):1093. PubMed ID: 2832966
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithrombin III and hepatocellular carcinoma.
    Lefrère JJ; Conard J; Lerable J; Samama M
    Thromb Haemost; 1989 Sep; 62(2):817. PubMed ID: 2554522
    [No Abstract]   [Full Text] [Related]  

  • 3. [A dysfunctional antithrombin III in patient with hepatoma].
    Matsuo T; Ohoki Y; Yamada T; Kobayashi H
    Rinsho Ketsueki; 1984 Aug; 25(8):1244-9. PubMed ID: 6096595
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma].
    Nakamura K; Makino I
    Ryoikibetsu Shokogun Shirizu; 1995; (7):265-8. PubMed ID: 8749467
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum selenium concentration in patients with liver cirrhosis and hepatocellular carcinoma.
    Buljevac M; Romić Z; Vucelić B; Banić M; Krznarić Z; Plesko S
    Acta Med Croatica; 1996; 50(1):11-4. PubMed ID: 8776109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis.
    Kuwahara T; Sakai T; Majima Y; Hirai K; Tanikawa K
    Hepatogastroenterology; 1993 Aug; 40(4):347-51. PubMed ID: 7691701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood coagulation and fibrinolysis in Ugandan patients with cirrhosis and hepatocellular carcinoma.
    Alpidovsky VK; Vogel CL; Sadikali F; Primack A
    East Afr Med J; 1974 May; 51(5):396-408. PubMed ID: 4367587
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pseudoleukemic hyperleukocytosis disclosing hepatocellular carcinoma].
    Sylvain C; Guilhot F; Carretier M; Verneau A; Poncin E; Beauchant M
    Gastroenterol Clin Biol; 1985 Apr; 9(4):368-9. PubMed ID: 2987074
    [No Abstract]   [Full Text] [Related]  

  • 9. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma.
    Mattera D; Capuano G; Colao A; Pivonello R; Manguso F; Puzziello A; D'Agostino L
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):699-706. PubMed ID: 14974910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of serum copper, zinc and plasma fibrinogen in cirrhotic patients with and without hepatocellular carcinoma.
    Doğan UB; Cindoruk M; Dumlu S; Unlü R; Unal S
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):476-7. PubMed ID: 9494860
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinicopathological aspects of primary hepatocellular carcinoma occurring in patients with liver cirrhosis.
    Iwamura K
    Tokai J Exp Clin Med; 1982 Sep; 7(5):589-605. PubMed ID: 6190271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.
    Cheng BQ; Jia CQ; Liu CT; Lu XF; Zhong N; Zhang ZL; Fan W; Li YQ
    Dig Liver Dis; 2008 Jun; 40(6):446-52. PubMed ID: 18294942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma.
    Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Ono K; Kubo S
    J Hepatobiliary Pancreat Surg; 2006; 13(3):239-44. PubMed ID: 16708302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. May plasma cholesterol level be considered a neoplastic marker in liver disease from cirrhosis to hepatocellular carcinoma?
    Venturini I; Amedei R; Modonesi G; Cosenza R; Miglioli L; Cioni G; Zeneroli ML
    Ital J Gastroenterol Hepatol; 1999; 31(1):61-5. PubMed ID: 10091105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked episodic elevations of alpha-fetoprotein without hepatocellular carcinoma in a patient with hepatitis B.
    Wong CB; Attar BM; Shimoda SS
    Am J Gastroenterol; 1995 Jun; 90(6):1015-6. PubMed ID: 7539578
    [No Abstract]   [Full Text] [Related]  

  • 16. Some haematological observations of Kenyan hepatocellular carcinoma (HCC) patients.
    Mukiibi JM; Mwaungulu GS; Wankya BM
    East Afr Med J; 1982 Feb; 59(2):118-26. PubMed ID: 6290180
    [No Abstract]   [Full Text] [Related]  

  • 17. Vascular endothelial growth factor receptor-1 levels in hepatocellular carcinoma and correlations with clinicopathological features.
    Yolcu OF; Köklü S; Yüksel O; Coban S; Ayaz S; Akif Oztürk M; Benekli M
    Hepatogastroenterology; 2007; 54(77):1526-8. PubMed ID: 17708290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The problem of immunochemical diagnosis of primary cancer of the liver].
    Assekrutova IV; Abelev GI; Kraevskiĭ NA; Perova SD; Perevodchikova NI
    Vestn Akad Med Nauk SSSR; 1967; 22(5):75-81. PubMed ID: 4174294
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
    Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
    Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-fetoprotein and hepatocellular carcinoma.
    Colli A; Fraquelli M; Conte D
    Am J Gastroenterol; 2006 Aug; 101(8):1939; author reply 1940-1. PubMed ID: 16928257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.